Neurology Central

Aducanumab: Biogen to seek US FDA approval


Biogen (MA, USA) and Eisai Co. (Tokyo, Japan) have announced plans to pursue regulatory approval for aducanumab as a treatment for early Alzheimer’s disease (AD) after consultation with the US FDA. If approved, aducanumab would be the first line of therapy to reduce the clinical decline of AD and the first therapy to demonstrate the clinical benefit of removing amyloid beta.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.